Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial-Reference-Cited by-同舟云学术

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Published:2020-05-07 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Ma Jianhui,Song Yan,Shou Jianzhong,Bai Yuxian,Li Hanzhong,Xie Xiaodong,Luo Hong,Ren Xiubao,Liu Jiyan,Ye Dingwei,Bai Xianzhong,Fu Cheng,Qin Shukui,Wang Jinwan,Zhou Ai-Ping

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference40 articles.

1. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics;Linehan,2007

2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med.,2007

3. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med.,2013

4. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer;Eichelberg;Eur Urol.,2015

5. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma;Negrier;N Engl J Med.,1998

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

2. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial;eClinicalMedicine;2023-10

3. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review;European Urology;2023-10

4. Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells;Lipids in Health and Disease;2023-08-23

5. Research Progress of Anlotinib for Treating Gynecologic Malignancies;Advances in Clinical Medicine;2023